The Food and Drug Administration agrees to review a New Drug Application for Vyglxia, Biohaven’s experimental spinocerebellar ataxia treatment.
We are experiencing some temporary issues. The market data on this page is currently delayed.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again ·
Barrons.com
·
Courtesy photo
